The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Imminent announcement of US distributor should see a further surge in SP.
Product is now available across Europe via New Pharma and others. Just ordered some from them as I’m staying in France. Only 7 reviews so far, but mostly positive. Will give my honest opinion once tested. Boots must be selling thousands of packs per week, so could be in the tens of thousands across Europe. A trading update from FUM would be welcome.
Looking at the ingredients in eroxon, it should be very cheap to produce, so at £24+ retail the margins will be impressive. FUM should swing into profit very quickly and may even pay dividends. Only one way the SP is heading now (IMO of course!) Fill your pockets while you can.
Just checked out the eroxon web site and note a few changes since I last looked. States availability in UK but link just takes you to the product leaflet. However, suggests launch to be imminent. Like others here I’m heavily invested and need this to fly.
If I’ve read and understood this correctly, FUM have retained control of manufacturing through third party contractors and therefore supply Eroxon to their distribution partners at a distributor discounted price. There will no doubt be a recommended retail price, but the distributor is at liberty to discount.
I think the consensus was that Coopers et al, would manufacture product under licence and pay a royalty to FUM, but this doesn’t appear to be the case. Would be good to have this clarified.
Not to mention PPS make a profit, albeit small at circa £600K. AFC losses totalled c. £5 million.
PPS now expanding into huge new manufacturing facility and have growing order book, numerous awards, plus new and repeat customers. Looking forward to their next set of results, which if it shows a sustained growth path, should see a surge in SP and wider market interest.
At 10p I think this company is worth a punt, so long as you’re prepared to hold.
Now the RNS re: product launch is out, there should be no reason why Cooper Health can’t make a press release. They don’t seem keen on marketing, as their last PR was September 2020 and still no mention of Eroxon on their site. SP now a bargain!
Thanks for sharing that info Brugge. It’s reassuring to know the product works!
I’m amazed Farmaline have been given a massive competitive advantage by being first to market. The other sub suppliers must be fuming. I wonder if they’ve jumped the gun. Assured Pharmacy are still only saying they are working on an exciting new launch they can’t wait to tell us about.
I’m thinking it’s time to clear out some dead wood in my portfolio and go large on FUM.
Ask for a brochure? In which case that information would be in the public domain and I think their competitors would already know that. Clearly you’ve never run a commercial organisation. Pratt.
Just received a marketing email from Assured Pharmacy (ed drugs online) which reads “We’re working on an exciting new launch which we can’t wait to tell you about”. Wonder what it could be!
Once again no indication of the value of these orders or the sales potential generated by the MoU, so a meaningless RNS.
Hi, si I’m a novice trader, but can anyone explain to me how and why there can be 19 separate sell offs in bundles of precisely 2529 shares at the same price throughout the day. Seems odd.
Lot’s of blue, let’s hope it’s the touch paper!
It would be more informative to know the value of these orders, rather than just the number of units. I’d be willing to invest further with a bit more information.